Tiziana Life Sciences has signed a Memorandum of Understanding with Saudi Arabia's King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to study a combination therapy for multiple sclerosis (MS). The trial will focus on relapsing-remitting MS patients who respond poorly to anti-CD20 therapy alone, using Tiziana's intranasal foralumab, which has shown promise in reducing neuroinflammation. This collaboration expands Tiziana's MS research beyond its ongoing secondary progressive MS program, with Phase 2 trial results expected in October. The announcement boosted Tiziana's shares by over 18%.
Tiziana Life Sciences' partnership on MS therapy trial is presented alongside Pluang's health sector snapshot as of Sep 17, 2026 22:21 WIB. Among 91 priced health-sector US stocks, 65 rose and 25 fell. Notably, BioNano Genomics Inc (BNGO) gained 10.60% at USD 1.67 with a typical hold time of 49 days, contrasting with AbCellera Biologics Inc (ABCL) which rose 10.54% to USD 12.90 but saw 99% sell order activity. Novavax Inc (NVAX) increased 8.82% to USD 10.18, with a full buy order activity and a longer hold time of 59 days.
KB Home is set to report its Q3 2026 earnings on September 22, with analysts projecting a 45.3% drop in earnings per share to around $0.89 and a 20.2% decline in revenue to about $1.30 billion compared to last year. The consensus EPS estimate has rec...
An investment of $10,000 in Nebius when it resumed trading in 2024 has grown significantly to approximately $105,000 by 2026. This remarkable increase highlights Nebius's strong market performance over the two-year period. Investors who bought in at ...
W.P. Carey expects to invest over $1.9 billion in 2026, reflecting robust growth in its net lease property portfolio. Despite a slight reduction in its price target by Scotiabank to $76, the stock still shows potential upside from current levels. The...
Micron Technology is investing $10 billion over the next decade to establish Micron Research Labs, a new division focused on future memory architectures and advanced semiconductor manufacturing. The company shows strong financial health with a low de...
Impact Biomedical Inc. will conduct a 1-for-12.62 reverse stock split on September 23, 2026, consolidating shares without changing shareholder value. This move facilitates its planned merger with Zoar Ltd., with a Form F-4 registration filed with the...
